Yr Athro Ernest Choy

2023

• Ghosh, N. et al. 2023. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: a scoping review by the OMERACT irAE working group. Seminars in Arthritis and Rheumatism 58, article number: 152110. (10.1016/j.semarthrit.2022.152110)
• Taylor, P. C., Askari, A., Choy, E., Ehrenstein, M. R., Else, S. and Nisar, M. K. 2023. Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC Medicine 21(1), article number: 55. (10.1186/s12916-023-02746-5)
• Huizinga, T. et al. 2023. Clinical efficacy of sarilumab versus upadacitinib over 12 weeks: an indirect treatment comparison. Rheumatology and Therapy (10.1007/s40744-022-00521-1)
• Bamias, A. et al. 2023. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 11, article number: e005977. (10.1136/jitc-2022-005977)
• Takala, R., Ramji, D. P. and Choy, E. 2023. The beneficial effects of pine nuts and its major fatty acid, pinolenic acid, on inflammation and metabolic perturbations in inflammatory disorders. International Journal of Molecular Sciences 24(2), article number: 1171. (10.3390/ijms24021171)

2022

• Charles-Schoeman, C. et al. 2022. MACE et MTEV au cours du programme d?essais cliniques sur l?upadacitinib dans la polyarthrite rhumatoïde, le rhumatisme psoriasique et la spondylarthrite ankylosante. Revue du Rhumatisme 89(Supple), pp. A204-A205. (10.1016/j.rhum.2022.10.309)
• Das, D. and Choy, E. 2022. Non-inflammatory pain in inflammatory arthritis. Rheumatology (10.1093/rheumatology/keac671)
• Doebl, S., Hollick, R. J., Beasley, M., Choy, E., Macfarlane, G. J. and the PACFiND Study Investigators, . 2022. Comparing the impact of symptoms and health care experiences of people who have and have not received a diagnosis of fibromyalgia: A cross‐sectional survey within the PACFiND study. Arthritis Care and Research 74(11), pp. 1894-1902. (10.1002/acr.24723)
• Choy, E. et al. 2022. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab. Rheumatology (10.1093/rheumatology/keac659)
• Williams, D. et al. 2022. Identities of women who have an autoimmune rheumatic disease [ARD] during pregnancy planning, pregnancy and early parenting: A qualitative study. PLOS ONE 17(11), article number: e0263910. (10.1371/journal.pone.0263910)
• Cooksey, R. and Choy, E. 2022. Exploring gender differences, medical history, and treatments used in patients with fibromyalgia in the UK using primary-care data: a retrospective, population-based, cohort study. The Lancet Rheumatology 4(S1), article number: S20. (10.1016/s2665-9913(22)00296-x)
• Humby, F. et al. 2022. Rituximab versus tocilizumab and b-cell status in tnf-alpha inadequate-responder rheumatoid arthritis patients: the r4-ra rct. Efficacy and Mechanism Evaluation 9(7) (10.3310/gopl1729)
• Aleteha, D. et al. 2022. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.. Annals of the Rheumatic Diseases (10.1136/ard-2022-222784)
• Cooksey, R., Brophy, S., Kennedy, J., Seaborne, M. and Choy, E. 2022. Real-world use of an etanercept biosimilar including selective versus automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study. Rheumatology Advances in Practice 6(2), article number: rkac056. (10.1093/rap/rkac056)
• Galloway, J., Raine, T., Rivett, L., Roberts, J., Dews, S. and Choy, E. H. 2022. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.. Clinical and Experimental Rheumatology 40(7), pp. 1432-1441. (10.55563/clinexprheumatol/0jdyse)
• Goebel, A. et al. 2022. Research recommendations following the discovery of pain sensitizing IgG autoantibodies in fibromyalgia syndrome. Pain Medicine 23(6), pp. 1084-1094., article number: pnab338. (10.1093/pm/pnab338)
• Cooksey, R., Underwood, J., Brophy, S., Atkinson, M., Kennedy, J. and Choy, E. 2022. Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality. Rheumatology 61(SI2), pp. SI120-SI128., article number: keac283. (10.1093/rheumatology/keac283)
• Pickles, T. et al. 2022. P089 Patient-reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines. Presented at: British Society for Rheumatology Annual Conference 2022, Glasgow, Scotland, 25-27 April 2022Rheumatology Supplement 1, Vol. 61. pp. keac133.088., (10.1093/rheumatology/keac133.088)
• Takala, R. et al. 2022. Pinolenic acid exhibits Anti-inflammatory and Anti-atherogenic effects in Peripheral blood- derived Monocytes from patients with Rheumatoid Arthritis. Scientific Reports 12, article number: 8807. (10.1038/s41598-022-12763-8)
• Rivellese, F. et al. 2022. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 r4ra randomized trial. Nature Medicine 28, pp. 1256–1268. (10.1038/s41591-022-01789-0)
• Takala, R., Ramji, D. P., Andrews, R., Zhou, Y., Burston, J. and Choy, E. 2022. Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis. Rheumatology 61(3), pp. 992-1004. (10.1093/rheumatology/keab467)
• Pickles, T. et al. 2022. Patient reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines. RMD Open 8(1), article number: e002093. (10.1136/rmdopen-2021-002093)
• Guillo, L., Rabaud, C., Choy, E. H., D'Amico, F., Danese, S., Ng, S. C. and Peyrin-Biroulet, L. 2022. Herpes Zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. Clinical Gastroenterology and Hepatology 20(3), pp. 481-490. (10.1016/j.cgh.2020.10.027)
• Holman, A. J., Keystone, E., Choy, E., Furst, D., Taylor, P. and Gaylis, N. 2022. Considering immuno-autonomics in stratifying successful treatment of rheumatoid arthritis with tumor necrosis factor inhibition: comment on Cohen et al. Rheumatol Ther 2021 June 19. Rheumatology and Therapy 9, pp. 305-307. (10.1007/s40744-021-00386-w)
• Nagy, G. et al. 2022. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 81(1), pp. 20-33. (10.1136/annrheumdis-2021-220973)

2021

• Rehberg, M. et al. 2021. Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatology and Therapy 8, pp. 1661-1675. (10.1007/s40744-021-00361-5)
• Maxwell, L. J. et al. 2021. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Seminars in Arthritis and Rheumatism 51(6), pp. 1320-1330. (10.1016/j.semarthrit.2021.08.011)
• Quartuccio, L. and Choy, E. H. 2021. Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis. Rheumatology 60(11), pp. 4953-4955., article number: keab425. (10.1093/rheumatology/keab425)
• Ceeraz, S., Thompson, C. R., Beatson, R. and Choy, E. H. 2021. Harnessing CD8+CD28− regulatory T cells as a tool to treat autoimmune disease. Cells 10(11), article number: 2973. (10.3390/cells10112973)
• Pedersen, M. B. et al. 2021. Biopsychosocial rehabilitation for inflammatory arthritis and osteoarthritis: A systematic review and meta?analysis of randomized trials. Arthritis Care and Research (10.1002/acr.24816)
• Fernández-Gutiérrez, F. et al. 2021. Mining primary care electronic health records for automatic disease phenotyping: a transparent machine learning framework. Diagnostics 11(10), article number: 1908. (10.3390/diagnostics11101908)
• Rehberg, M. et al. 2021. Correction to: identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatology and Therapy 8(4), pp. 1921–1922. (10.1007/s40744-021-00389-7)
• Bedke, J. et al. 2021. Partial response and stable disease correlate with positive outcomes in Atezolizumab-treated patients with advanced urinary tract carcinoma. European Urology Focus 7(5), pp. 1084-0191. (10.1016/j.euf.2020.10.009)
• D'Amico, F. et al. 2021. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmunity Reviews 20(7), article number: 102849. (10.1016/j.autrev.2021.102849)
• Cooksey, R., Rahman, M. A., Kennedy, J., Brophy, S. and Choy, E. 2021. Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK. Rheumatology Advances in Practice 5(2), article number: rkab042. (10.1093/rap/rkab042)
• Sarzi-Puttini, P. et al. 2021. Diagnostic and therapeutic care pathway for fibromyalgia. Clinical and Experimental Rheumatology 39(3) (10.55563/clinexprheumatol/zcp5hz)
• Sarzi-Puttini, P. et al. 2021. Fibromyalgia position paper. Clinical and Experimental Rheumatology 39(3 Supp), pp. 186-193. (10.55563/clinexprheumatol/i19pig)
• Bamias, A. et al. 2021. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO Open 6(3), article number: 100152. (10.1016/j.esmoop.2021.100152)
• Xu, C. et al. 2021. Differential binding of sarilumab and tocilizumab to IL-6Rα and effects of receptor occupancy on clinical parameters. Journal of Clinical Pharmacology 61(5), pp. 714-724. (10.1002/jcph.1795)
• Pedley, R. et al. 2021. Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. Rheumatology Advances in Practice 5(2), article number: rkaa063. (10.1093/rap/rkaa063)
• Pope, J. E. and Choy, E. H. 2021. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Seminars in Arthritis and Rheumatism 51(1), pp. 219-229. (10.1016/j.semarthrit.2020.11.005)
• Simon, L. S., Taylor, P. C., Choy, E. H., Sebba, A., Quebe, A., Knopp, K. L. and Porreca, F. 2021. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 51(1), pp. 278-284. (10.1016/j.semarthrit.2020.10.008)
• Choy, E. et al. 2021. Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatology 5(1), article number: 3. (10.1186/s41927-020-00173-0)
• Kostine, M. et al. 2021. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases 80(1), pp. 36-48. (10.1136/annrheumdis-2020-217139)
• Nagy, G. et al. 2021. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 80(1), pp. 31-35. (10.1136/annrheumdis-2020-217344)
• Humby, F. et al. 2021. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397(10271), pp. 305-317. (10.1016/S0140-6736(20)32341-2)

2020

• Pitzalis, C., Choy, E. H. S. and Buch, M. H. 2020. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nature Reviews Rheumatology 16(10), pp. 590-599. (10.1038/s41584-020-0491-4)
• Loriot, Y. et al. 2020. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European Journal of Cancer 138, pp. 202-211. (10.1016/j.ejca.2020.07.023)
• Leung, M., Choy, E. H. and Lau, C. 2020. Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation. Seminars in Arthritis and Rheumatism 50(4), pp. 749-758. (10.1016/j.semarthrit.2020.03.010)
• Ho, K. Y. et al. 2020. Practice advisory on the appropriate use of NSAIDs in primary care. Journal of Pain Research 2020(13), pp. 1925-1939. (10.2147/JPR.S247781)
• Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R. and Kishimoto, T. 2020. Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology 16, pp. 335-345. (10.1038/s41584-020-0419-z)
• Thompson, C., Davies, R., Williams, A., Jones, G. and Choy, E. H. S. 2020. CD28− Cells are increased in early rheumatoid arthritis and are linked with cytomegalovirus status. Frontiers in Medicine 7, article number: 129. (10.3389/fmed.2020.00129)
• Winthrop, K. L. et al. 2020. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Annals of the Rheumatic Diseases 79, pp. 669-671. (10.1136/annrheumdis-2019-216566)
• Monnet, E. et al. 2020. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Annals of the Rheumatic Diseases 79, pp. 316-323. (10.1136/annrheumdis-2019-216487)
• Pell, B., Williams, D., Phillips, R., Sanders, J., Edwards, A., Choy, E. and Grant, A. 2020. Using visual timelines in telephone interviews: Reflections and lessons learned from the STAR Family Study. International Journal of Qualitative Methods 19, pp. 1-11. (10.1177/1609406920913675)

2019

• Lliso-Ribera, G. et al. 2019. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Annals of the Rheumatic Diseases 78(12), pp. 1642-1652. (10.1136/annrheumdis-2019-215751)
• Choy, E. H. and Dures, E. 2019. Fatigue in rheumatoid arthritis. Rheumatology 58(S5), pp. v1-v2. (10.1093/rheumatology/kez314)
• Demmler, J. C., Atkinson, M. D., Reinhold, E. J., Choy, E., Lyons, R. A. and Brophy, S. T. 2019. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open 9(11), article number: e031365. (10.1136/bmjopen-2019-031365)
• Choy, E. H. 2019. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology 58(S5), pp. v51-v55. (10.1093/rheumatology/kez389)
• Ramjeeawon, A. and Choy, E. 2019. Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing. Clinical Rheumatology 38(11), pp. 3153-3159. (10.1007/s10067-019-04656-5)
• Williams, D. et al. 2019. “Nobody knows, or seems to know how rheumatology and breastfeeding works”: Women's experiences of breastfeeding whilst managing a long-term limiting condition – A qualitative visual methods study. Midwifery 78, pp. 91-96. (10.1016/j.midw.2019.08.002)
• Pickles, T. et al. 2019. Adaptive trial designs in rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology 46(10), pp. 1406-1408., article number: jrheum.181054. (10.3899/jrheum.181054)
• Hewlett, S. et al. 2019. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technology Assessment 23(57), pp. 1. (10.3310/hta23570)
• Choy, E. H. 2019. Using biologics safely. Rheumatology 58(9), pp. 1515-1516. (10.1093/rheumatology/kez129)
• Lewis, M. J. et al. 2019. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Reports 28(9), pp. 2455-2470.e5. (10.1016/j.celrep.2019.07.091)
• Mease, P. et al. 2019. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. European Journal of Rheumatology 6(3), pp. 113-121. (10.5152/eurjrheum.2019.19057)
• Baerwald, C. and Choy, E. 2019. Generalised musculoskeletal problems. Best Practice & Research Clinical Rheumatology 33(3), article number: 101441. (10.1016/j.berh.2019.101441)
• Choy, E. et al. 2019. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clinical and Experimental Rheumatology 37(4), pp. 694-407., article number: CER11619.
• Tarp, S. et al. 2019. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism 48(6), pp. 958-966. (10.1016/j.semarthrit.2018.10.002)
• Choy, E. H. 2019. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology 58(6), pp. 953-962., article number: key339. (10.1093/rheumatology/key339)
• Choy, E. et al. 2019. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology 58(6), pp. 1056-1064. (10.1093/rheumatology/key393)
• Humby, F. et al. 2019. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases 78(6), pp. 761-772. (10.1136/annrheumdis-2018-214539)
• Macfarlane, G. J. et al. 2019. AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatology 3(1), pp. -., article number: 19. (10.1186/s41927-019-0066-7)
• Isaacs, J. D. et al. 2019. Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. Rheumatology Advances in Practice 3(1), pp. -. (10.1093/rap/rkz010)
• Sternberg, C. N. et al. 2019. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. European Urology (10.1016/j.eururo.2019.03.015)
• Hewlett, S. et al. 2019. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Annals of the Rheumatic Diseases 78(4), pp. 465-472. (10.1136/annrheumdis-2018-214469)
• Jones, S. A., Takeuchi, T., Aletaha, D., Smolen, J., Choy, E. H. and McInnes, I. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
• Takeuchi, T., Smolen, J. S., Choy, E., Aletaha, D., McInnes, I. and Jones, S. 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2(1), pp. 7-11. (10.1136/conmed-2018-000002)
• Smolen, J. S., Aletaha, D., Choy, E., Jones, S., Takeuchi, T. and McInnes, I. 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2(1), pp. 12-18. (10.1136/conmed-2018-000003)
• Choy, E., Jones, S., Aletaha, D., Takeuchi, T., McInnes, I. and Smolen, J. S. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2(1), pp. 19-23. (10.1136/conmed-2018-000004)
• Choy, E. et al. 2019. The need for comparative data in spondyloarthritis. Arthritis Research and Therapy 21(1), article number: 32. (10.1186/s13075-019-1812-3)
• Strand, V. et al. 2019. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research 8(7), pp. 497-510. (10.2217/cer-2018-0141)
• Choy, E. et al. 2019. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open 5(1), article number: e000798. (10.1136/rmdopen-2018-000798)

2018

• Piguet, V. and Choy, E. 2018. Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?. British Journal of Dermatology 179(6), pp. 1233-1234. (10.1111/bjd.16230)
• Thompson, C., Piguet, V. and Choy, E. 2018. The pathogenesis of dermatomyositis. British Journal of Dermatology 179(6), pp. 1256-1262. (10.1111/bjd.15607)
• Cooksey, R. et al. 2018. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Seminars in Arthritis and Rheumatism 48(3), pp. 367-373. (10.1016/j.semarthrit.2018.03.005)
• Jordan, L. A. et al. 2018. Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis. Rheumatology 57(11), pp. 2042-2052. (10.1093/rheumatology/key196)
• Macfarlane, G. J. et al. 2018. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology 57(11), pp. 1982-1990., article number: key206. (10.1093/rheumatology/key206)
• Vollenhoven, R. et al. 2018. Evaluation of the short‐, mid‐, and long‐term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis and Rheumatology 71(5), pp. 685-695. (10.1002/art.40780)
• McInnes, I. B. et al. 2018. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research 7(11), pp. 1107-1123. (10.2217/cer-2018-0075)
• Just, S. A. et al. 2018. Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. RMD Open 4(2), pp. e000799. (10.1136/rmdopen-2018-000799)
• Pamfil, C. and Choy, E. 2018. Functional MRI in rheumatic disease with a focus on fibromyalgia. Clinical and Experimental Rheumatology 36 Sup(5), pp. 82-85., article number: 114.
• Phillips, R. et al. 2018. Identifying the unmet information and support needs of women with autoimmune rheumatic diseases during pregnancy planning, pregnancy and early parenting: mixed-methods study. BMC Rheumatology 2, article number: 21. (10.1186/s41927-018-0029-4)
• Pickles, T., Christensen, R., Tam, L., Simon, L. S. and Choy, E. H. 2018. Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatology Advances in Practice 2(2), article number: rky045. (10.1093/rap/rky045)
• Dolton, G. et al. 2018. Optimized peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells. Frontiers in Immunology 9, article number: 1378. (10.3389/fimmu.2018.01378)
• Phillips, R. et al. 2018. Reaching a consensus on research priorities for supporting women with autoimmune rheumatic diseases during pre-conception, pregnancy and early parenting: A Nominal Group Technique exercise with lay and professional stakeholders. Wellcome Open Research 3, article number: 75. (10.12688/wellcomeopenres.14658.1)
• O'Mahony, A., John, M. R., Cho, H., Hashizume, M. and Choy, E. H. 2018. Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. Journal of Translational Medicine 16, article number: 156. (10.1186/s12967-018-1532-5)
• Nurmohamed, M., Choy, E., Lula, S., Kola, B., DeMasi, R. and Accossato, P. 2018. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Safety 41(5), pp. 473-488. (10.1007/s40264-017-0628-9)
• Arnold, L. M. et al. 2018. An evidence-based review of pregabalin for the treatment of fibromyalgia. Current Medical Research and Opinion 34(8), pp. 1397-1409. (10.1080/03007995.2018.1450743)
• Choy, E. et al. 2018. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology 57(3), pp. 499-507. (10.1093/rheumatology/kex443)
• Sarzi-Puttini, P., Atzeni, F., Masala, I. F., Salaffi, F., Chapman, J. and Choy, E. 2018. Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. Autoimmunity Reviews 17(1), pp. 33-35. (10.1016/j.autrev.2017.11.007)

2017

• Choy, E. H. S. and Calabrese, L. H. 2017. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rhuematology 57(11), pp. 1885-1895. (10.1093/rheumatology/kex391)
• Macfarlane, G. J. et al. 2017. EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases 76(12), pp. -., article number: e54. (10.1136/annrheumdis-2017-211587)
• Choy, E. H. S., Bernasconi, C., Aassi, M., Molina, J. F. and Epis, O. M. 2017. Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic in a global comparative observational study. Arthritis Care & Research 69(10), pp. 1484-1494. (10.1002/acr.23303)
• Cohen, S. et al. 2017. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Annals of the Rheumatic Diseases 76(10), pp. 1679-1687. (10.1136/annrheumdis-2016-210459)
• Winthrop, K. L. et al. 2017. The safety and immunogenicity of live Zoster Vaccination in patients with rheumatoid arthritis before starting Tofacitinib: a randomized phase II trial. Arthritis & Rheumatology 69(10), pp. 1969-1977. (10.1002/art.40187)
• Orr, C. et al. 2017. Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology 13(8), pp. 463-475. (10.1038/nrrheum.2017.115)
• Sime, K., Choy, E. and Williams, A. 2017. Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. Adipocyte 6(2), pp. 87-101. (10.1080/21623945.2017.1295174)
• Kosek, E. et al. 2017. Lower placebo responses after long-term exposure to fibromyalgia pain. Journal of Pain 18(7), pp. 835-843. (10.1016/j.jpain.2017.02.434)
• Burmester, G. R. et al. 2017. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76, pp. 1078-1085. (10.1136/annrheumdis-2016-210297)
• Fleischmann, R. F. et al. 2017. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatology and Therapy 4(1), pp. 57-69. (10.1007/s40744-017-0060-8)
• Kia, S. and Choy, E. 2017. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines 5(2), article number: 20. (10.3390/biomedicines5020020)
• Choy, E. et al. 2017. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 56(5), pp. 689-697. (10.1093/rheumatology/kew271)
• Low, A. S. L. et al. 2017. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76(4), pp. 654-660. (10.1136/annrheumdis-2016-209784)
• Macfarlane, G. J. et al. 2017. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases 76(2), pp. 318-328. (10.1136/annrheumdis-2016-209724)

2016

• Leung, A. M. H., Farewell, D., Lau, C. S. and Choy, E. H. S. 2016. Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. Rhuematology 55(11), pp. 1954-1958. (10.1093/rheumatology/kew279)
• Rawlings, C., Davies, R. and Choy, E. 2016. Anti cytokine therapy in chronic inflammatory arthritis. Cytokine 86, pp. 92-99. (10.1016/j.cyto.2016.07.015)
• Owen, E., Choy, E. and Piguet, V. 2016. Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making. British Journal of Dermatology 175(4), pp. 665-666. (10.1111/bjd.14917)
• Taylor, A. M. et al. 2016. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain 157(9), pp. 1836-1850. (10.1097/j.pain.0000000000000577)
• Porter, D. et al. 2016. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388(10041), pp. 239-247. (10.1016/S0140-6736(16)00380-9)
• Choy, E. H. 2016. Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia. Pain Management 6(4), pp. 339. (10.2217/pmt-2016-0009)
• Almeida, C. et al. 2016. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews (10.1002/14651858.CD008334.pub2)
• Tarp, S. et al. 2016. Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism 46(6), pp. 699-708. (10.1016/j.semarthrit.2016.09.003)
• Zhou, S. et al. 2016. Defining disease phenotypes in primary care electronic health records by a machine learning approach: A case study in identifying rheumatoid arthritis. PLOS ONE 11(5), pp. e0154515. (10.1371/journal.pone.0154515)
• Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
• Bykerk, V. P. et al. 2016. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open 2(1), article number: e000225. (10.1136/rmdopen-2015-000225)
• Taylor, A. et al. 2016. Defining chronic pain reply. Journal of Rheumatology 43(4), pp. 826-827. (10.3899/jrheum.151456)
• Marchettini, P. et al. 2016. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?. European Journal of Pain 20(3), pp. 472-482. (10.1002/ejp.763)
• Liu, X., Jones, G. W., Choy, E. H. and Jones, S. A. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28(2), pp. 152-160. (10.1097/BOR.0000000000000255)
• Arnold, L. M., Gebke, K. B. and Choy, E. 2016. Fibromyalgia: management strategies for primary care providers. International Journal of Clinical Practice 70(2), pp. 99-112. (10.1111/ijcp.12757)
• Ravindran, V. and Choy, E. 2016. Modified-release prednisone in rheumatoid arthritis: Rationale for chronotherapy, mechanistic considerations, and clinical implications. Indian Journal of Rheumatology 11(4), pp. 216-221.

2015

• Taylor, A. M. et al. 2015. Is chronic pain a disease in its own right? Discussions from a Pre-OMERACT 2014 Workshop on chronic pain. Journal of Rheumatology 42(10), pp. 1947-1953. (10.3899/jrheum.141328)
• Phillips, K. et al. 2015. Harmonizing pain outcome measures: results of the Pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the Cochrane Musculoskeletal Group and OMERACT. Journal of Rheumatology 42(10), pp. 1943-1946., article number: 194386. (10.3899/jrheum.141386)
• Choy, E., Bernasconi, C., Aassi, M., Molina, J. F. and Epis, O. M. 2015. Treatment of Rheumatoid Arthritis with an anti-tumour necrosis factor agent or Tocilizumab as first biologic therapy: Action, a global comparative observational study. Rheumatology 55(Supp 1), pp. 101-102. (10.1093/rheumatology/kew144.023)
• Hewlett, S. et al. 2015. Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approaches. BMJ Open 5(8), article number: e009061. (10.1136/bmjopen-2015-009061)
• Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. and Harris, C. L. 2015. Response to comment on 'Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis'. Journal of Immunology 195(1), pp. 4-4. (10.4049/jimmunol.1500968)
• Ibrahim, F. et al. 2015. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rhuematology 54(6), pp. 1050-1055. (10.1093/rheumatology/keu442)
• Choy, E. H. S. 2015. The role of sleep in pain and fibromyalgia. Nature Reviews Rheumatology 11(9), pp. 513-520. (10.1038/nrrheum.2015.56)
• Collins, F. L., Williams, J., Bloom, A. C., Stone, M. D., Choy, E. H. S., Wang, E. C. Y. and Williams, A. S. 2015. Death Receptor 3 (TNFRSF25) Increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. Journal of Immunology Research 2015, pp. -., article number: 901679. (10.1155/2015/901679)
• Giles, J., Choy, E. H. S., Van Den Berg, C., Morgan, B. P. and Harris, C. L. 2015. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. The Journal of Immunology 194(7), pp. 3029-3034. (10.4049/jimmunol.1402956)

2014

• Lipkovich, I. A., Choy, E., Van Wambeke, P., Deberdt, W. and Sagman, D. 2014. Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients. BMC Musculoskeletal Disorders 15, article number: 450. (10.1186/1471-2474-15-450)
• Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. and Harris, C. L. 2014. Functional analysis of a complement polymorphism (rs17611) associated with Rheumatoid Arthritis. Immunology 143(s2), pp. 181-182. (10.1111/imm.12407)
• Jensen, K. B. et al. 2014. Segregating the cerebral mechanisms of antidepressants and placebo in fibromyalgia. The Journal of Pain 15(12), pp. 1328-1337. (10.1016/j.jpain.2014.09.011)
• Baron, R. et al. 2014. Improving the primary care physicians' decision making for fibromyalgia in clinical practice: development and validation of the Fibromyalgia Detection (FibroDetect®) screening tool. Health and Quality of Life Outcomes 12, article number: 128. (10.1186/s12955-014-0128-x)
• Lie, E. et al. 2014. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. Annals of the Rheumatic Diseases 73, pp. 1781. (10.1136/annrheumdis-2013-203496)
• Kirwan, J. R. et al. 2014. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. Journal of Rheumatology 41(5), pp. 994-999. (10.3899/jrheum.131309)
• Tugwell, P. et al. 2014. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. Journal of Rheumatology 41(5), pp. 1000-1004. (10.3899/jrheum.131310)
• Bykerk, V. P. et al. 2014. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare Workshop. Journal of Rheumatology 41(4), pp. 799-809. (10.3899/jrheum.131252)
• Kirwan, J. R. et al. 2014. Updating the OMERACT filter: implications for patient-reported outcomes. Journal of Rheumatology 41(5), pp. 1011-1015. (10.3899/jrheum.131312)
• Davies, R. and Choy, E. 2014. Clinical experience of IL-6 blockade in rheumatic diseases: implications on IL-6 biology and disease pathogenesis. Seminars in Immunology 26(1), pp. 97-104. (10.1016/j.smim.2013.12.002)
• Rawlings, C. and Choy, E. 2014. The future of biological agents in the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology 9(5), pp. 475-486. (10.2217/ijr.14.32)

2013

• Bari, S. F. and Choy, E. H. S. 2013. Outcome measures in rheumatoid arthritis. Indian Journal of Rheumatology 8(SUPPL1), pp. S31-S35. (10.1016/j.injr.2013.11.011)
• van der Maas, A. et al. 2013. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases 72(11), pp. 1800-1805. (10.1136/annrheumdis-2012-202281)
• Gullick, N., Abozaid, H., Jayaraj, D., Evans, H., Scott, D., Choy, E. H. S. and Taams, L. 2013. Enhanced and persistent levels of IL-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clinical and Experimental Immunology 174(2), pp. 292-301. (10.1111/cei.12167)
• Ceeraz, S., Hall, C., Choy, E. H. S., Spencer, J. and Corrigall, V. 2013. Defective CD8+CD28?regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clinical and Experimental Immunology 174(1), pp. 18-26. (10.1111/cei.12161)
• Choy, E. H. et al. 2013. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Research and Therapy 15(5), article number: R132. (10.1186/ar4312)
• Smolen, J. et al. 2013. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases 72(4), pp. 482-492. (10.1136/annrheumdis-2012-202469)
• Petzke, F. et al. 2013. Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia. Scandinavian Journal of Pain 4(2), pp. 65-74. (10.1016/j.sjpain.2012.10.002)
• Choy, E. H. S., Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9(3), pp. 154-163. (10.1038/nrrheum.2013.8)
• Jensen, K. B. et al. 2013. Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain. Arthritis & Rheumatism 65(12), pp. 3293-3303. (10.1002/art.38170)

2012

• Collins, F., Stone, M. D., Goodfellow, R. M., Choy, E. H. S., Wang, E. C. Y. and Williams, A. S. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64(10), pp. S768-S768.
• Spaeth, M., Bennett, R. M., Benson, B. A., Wang, Y. G., Lai, C. and Choy, E. H. S. 2012. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: Results of an international phase 3 trial. Annals of the Rheumatic Diseases 71(6), pp. 935-942. (10.1136/annrheumdis-2011-200418)

2011

• Choy, E. H. S., Marshall, D., Gabriel, Z. L., Mitchell, S. A., Gylee, E. and Dakin, H. A. 2011. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Seminars in Arthritis and Rheumatism 41(3), pp. 335-345.e6. (10.1016/j.semarthrit.2011.06.003)
• Paringe, V., Bloom, A. C., Choy, E. H. S., Morgan, B. P. and Williams, A. S. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
• Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.

2010

• Jensen, K. B. et al. 2010. Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain. Arthritis & Rheumatism 62(11), pp. 3488-3495. (10.1002/art.27649)

2008

• Choy, E. H. S., Khoshaba, B., Cooper, D., MacGregor, A. and Scott, D. L. 2008. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. Arthritis Care and Research 59(2), pp. 192-199. (10.1002/art.23342)
• Ravindran, V., Scott, D. L. and Choy, E. H. S. 2008. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Annals of the Rheumatic Diseases 67(6), pp. 855-859. (10.1136/ard.2007.072652)
• Choy, E. H. S., Smith, C. M., Farewell, V., Walker, D., Hassell, A., Chau, L. and Scott, D. L. 2008. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Annals of the Rheumatic Diseases 67(5), pp. 656-663. (10.1136/ard.2007.076299)